TFF Pharmaceuticals has announced agreements for feasibility studies with vaccine developer GreenLight Biosciences and with NeuroRx. TFF is performing studies to determine if dry powder formulations of GreenLight's mRNA COVID-19 vaccine candidate and NeuroRx's Zyesami aviptadil can be successfully created using TFF's thin film freezing technology. According to … [Read more...] about TFF Pharmaceuticals announces agreements for feasibility studies of mRNA vaccine candidate and aviptadil
Medical
The Gates Medical Research Institute to develop dry powder lung surfactant for the treatment of RDS in premature infants
The Lundquist Institute for Biomedical Innovation (TLI, formerly LABioMed) has licensed a dry powder synthetic lung surfactant formulation to The Bill & Melinda Gates Medical Research Institute (Gates MRI), TLI said. Gates MRI plans to develop the inhalation powder for the treatment of respiratory distress syndrome (RDS) in premature infants in low- and … [Read more...] about The Gates Medical Research Institute to develop dry powder lung surfactant for the treatment of RDS in premature infants
AIM ImmunoTech initiates Phase 1 trial of intranasal Ampligen for COVID-19
AIM ImmunoTech announced that that the first subjects have been dosed in a Phase 1 safety study of an intranasal formulation of the company’s Ampligen rintatolimod, which the company is developing for the prevention and/or treatment of COVID-19. AIM announced plans for the study in January 2021. According to AIM, in vitro modeling has demonstrated that "clinically … [Read more...] about AIM ImmunoTech initiates Phase 1 trial of intranasal Ampligen for COVID-19
Pneumagen says preclinical study demonstrates the potential of Neumifil for COVID-19
According to Pneumagen, its Neumifil carbohydrate binding module (mCBM), which it is developing as a nasal spray for the prevention and treatment of respiratory infections, significantly reduced symptoms and weight loss in a hamster model of COVID-19. Researchers also found that Neumifill demonstrated high binding affinity for the ACE2 receptor and for the SARS-CoV-2 … [Read more...] about Pneumagen says preclinical study demonstrates the potential of Neumifil for COVID-19
Pulmatrix announces development plans for PUR3100 inhaled dry powder DHE for the treatment of migraine
Pulmatrix has announced plans for clinical development of PUR3100, an iSPERSE dry powder formulation of dihydroergotamine (DHE) for the treatment of migraine, after a PK study in dogs showed exposure kinetics similar to those of the Levadex (MAP0004, Semprana) DHE MDI. The company also provided updates on its development programs for Pulmazole and PUR1800 and said … [Read more...] about Pulmatrix announces development plans for PUR3100 inhaled dry powder DHE for the treatment of migraine
FDA clears Sorrento’s IND for Phase 1 trial of STI-2099 intranasal antibody against COVID-19
Sorrento Therapeutics said that the FDA has cleared its IND for a Phase 1 study of STI-2099 intranasal neutralizing antibody (CoviDrops) in healthy volunteers and in patients with mild COVID-19. The company said that it plans to study STI-2099 by itself or combined with an IV formulation of the antibody. In October 2020, Sorrento announced that STI-2099 reduced the … [Read more...] about FDA clears Sorrento’s IND for Phase 1 trial of STI-2099 intranasal antibody against COVID-19
Positive Phase 1 results for Atossa’s AT-301 nasal spray
Atossa Therapeutics announced that a two-week Phase 1 study evaluating the safety of two dose levels of the company's AT-301 nasal spray in healthy volunteers demonstrated that the nasal spray was safe and well tolerated. The company announced in August 2020 that it had received approval for the Phase 1 trial of AT-301, which it is developing as an at-home treatment … [Read more...] about Positive Phase 1 results for Atossa’s AT-301 nasal spray
Virpax begins pre-clinical studies of intranasal enkephalin to support IND
Virpax Pharmaceuticals said that the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health has begun pre-clinical studies of Virpax's Envelta intranasal enkephalin to support an IND submission. Virpax signed a cooperative research and development agreement with NCATS in August 2020. Envelta is delivered via a single use … [Read more...] about Virpax begins pre-clinical studies of intranasal enkephalin to support IND
Aridis announces planned clinical development of inhaled mAb cocktail for COVID-19
Aridis Pharmaceuticals announced that it is now receiving preclinical support from the NIAID (National Institute of Allergy and Infectious Diseases) and CoVIC (Coronavirus Immunotherapy Consortium) for a nebulized monoclonal antibody cocktail for COVID-19 and that it plans to initiate a Phase 1/2/3 clinical trial in the second half of this year. The company also said … [Read more...] about Aridis announces planned clinical development of inhaled mAb cocktail for COVID-19
Clinical trial of intranasal niclosamide for the prevention of COVID-19 gets underway
According to Union therapeutics, the Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge have begun recruiting kidney patients for a clinical trial of Union's UNI91103 intranasal niclosamide for the prevention of COVID-19 in vulnerable patients. The PROTECT-V (PROphylaxis for vulnerable paTiEnts at risk of COVID-19 infecTion) trial is … [Read more...] about Clinical trial of intranasal niclosamide for the prevention of COVID-19 gets underway